Statement: At least 8 participants in the primary trial had a Central Nervous System (CNS) Progression Free Survival (PFS) >= 3 months.
Primary_evidence: Outcome Measurement:    Percent of Participants With Central Nervous System (CNS) Progression Free Survival (PFS)   The study team will assess the percent of participants without CNS progression at 3 months. The study team will generate a Kaplan- Meier curve of CNS PFS and estimate the PFS and 95% confidence interval (CI) of the PFS. Response and progression by MR were evaluated using WHO/modified McDonald's criteria.   Time frame: At 12 weeks Results 1:    Arm/Group Title: Eribulin Mesylate   Arm/Group Description: The recommended starting dose of eribulin mesylate is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate   Eribulin Mesylate: Most subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.   MRI: An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate   Pre-Medication: Zofran: Zofran at 8mg orally. Given at the discretion of the treating physician   Pre-Medication: Decadron: decadron at 8mg orally. Given at the discretion of the treating physician   Overall Number of Participants Analyzed: 9   Measure Type: Number   Unit of Measure: percentage of participants  88.9        (51 to 99.7)